By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

Beyond the physical, a prostate cancer diagnosis carries significant emotional weight. Understanding this spectrum of ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...